Effects of fibrates in kidney disease: a systematic review and meta-analysis
Min Jun,Bin Zhu,Marcello Tonelli,Meg Jardine,Anushka Patel,Bruce Neal,Thaminda Liyanage,Anthony C Keech,Alan Cass,Vlado Perkovic +9 more
Reads0
Chats0
TLDR
It is suggested that fibrates have a place in reducing cardiovascular risk in people with mild-to-moderate CKD and reduce albuminuria and reversibly increase serum creatinine but the effects on major kidney outcomes remain unknown.About:
This article is published in Journal of the American College of Cardiology.The article was published on 2012-11-13 and is currently open access. It has received 151 citations till now. The article focuses on the topics: Fibrate & Kidney disease.read more
Citations
More filters
Journal ArticleDOI
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskThe Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
François Mach,Colin Baigent,Alberico L. Catapano,Konstantinos C. Koskinas,Manuela Casula,Lina Badimon,M. John Chapman,Guy De Backer,Victoria Delgado,Brian A. Ference,Ian D. Graham,Alison Halliday,Ulf Landmesser,Borislava Mihaylova,Terje R. Pedersen,Gabriele Riccardi,Dimitrios J. Richter,Marc S. Sabatine,Marja-Riitta Taskinen,Lale Tokgozoglu,Olov Wiklund,Christian Mueller,Heinz Drexel,Victor Aboyans,Alberto Corsini,Wolfram Doehner,Michel Farnier,Bruna Gigante,Meral Kayıkçıoğlu,Goran Krstacic,Ekaterini Lambrinou,Basil S. Lewis,Josep Masip,Philippe Moulin,Steffen E. Petersen,Anna Sonia Petronio,Massimo F Piepoli,Xavier Pintó,Lorenz Räber,Kausik K. Ray,Željko Reiner,Walter F Riesen,Marco Roffi,Jean-Paul Schmid,Evgeny Shlyakhto,Iain A. Simpson,Erik S.G. Stroes,Isabella Sudano,Alexandros D Tselepis,Margus Viigimaa,Cecile Vindis,Alexander Vonbank,Michal Vrablik,Mislav Vrsalovic,José Luis Zamorano,Jean-Philippe Collet,Stephan Windecker,Veronica Dean,Donna Fitzsimons,Chris P Gale,Diederick E. Grobbee,Sigrun Halvorsen,Gerhard Hindricks,Bernard Iung,Peter Jüni,Hugo A. Katus,Christophe Leclercq,Maddalena Lettino,Béla Merkely,Miguel Sousa-Uva,Rhian M. Touyz,Djamaleddine Nibouche,Parounak H. Zelveian,Peter Siostrzonek,Ruslan Najafov,Philippe van de Borne,Belma Pojskic,Arman Postadzhiyan,Lambros Kypris,Jindřich Špinar,Mogens Lytken Larsen,Hesham Salah Eldin,Timo E. Strandberg,Jean Ferrières,Rusudan Agladze,Ulrich Laufs,Loukianos S. Rallidis,Laszlo Bajnok,Thorbjorn Gudjonsson,Vincent Maher,Yaakov Henkin,Michele Massimo Gulizia,Aisulu Mussagaliyeva,Gani Bajraktari,Alina Kerimkulova,Gustavs Latkovskis,Omar Hamoui,Rimvydas Šlapikas,Laurent Visser,P. Dingli,Victoria Ivanov,Aneta Boskovic,Mbarek Nazzi,Frank L.J. Visseren,Irena Mitevska,Kjetil Retterstøl,Piotr Jankowski,Ricardo Fontes-Carvalho,Dan Gaita,Marat V. Ezhov,Marina Foscoli,Vojislav Giga,Daniel Pella,Zlatko Fras,Leopoldo Pérez de Isla,Emil Hagström,Roger Lehmann,Leila Abid,Oner Ozdogan,Olena Mitchenko,Riyaz S. Patel +120 more
Journal ArticleDOI
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
Alison Halliday,Colin Baigent,François Mach,Borislava Mihaylova,Borislava Mihaylova,Brian A. Ference +5 more
TL;DR: Authors/Task Force Members (François Macha, Colin Baigentb,∗∗,2, Alberico L. Catapanoc), ESC Committee for Practice Guidelines (CPG) (Stephan Windeckeraa), ESC National Cardiac Societies (Djamaleddine Nibouchean, Parounak H. Patelcl)
Journal ArticleDOI
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Alberico L. Catapano,Ian D. Graham,Guy De Backer,Olov Wiklund,M. John Chapman,Heinz Drexel,Arno W. Hoes,Catriona Jennings,Ulf Landmesser,Terje R. Pedersen,Željko Reiner,Gabriele Riccardi,Marja-Riitta Taskinen,Lale Tokgozoglu,W. M. Monique Verschuren,Charalambos Vlachopoulos,David R. Wood,José Luis Zamorano +17 more
TL;DR: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology and European Atherosclerosis Society and EAS and ABI : ankle-brachial index are formed.
Journal ArticleDOI
Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development
Hyun Mi Kang,Seon Ho Ahn,Peter S. Choi,Yi-An Ko,Seung Hyeok Han,Frank Chinga,Ae Seo Deok Park,Jianling Tao,Kumar Sharma,James Pullman,Erwin P. Bottinger,Ira J. Goldberg,Katalin Susztak +12 more
TL;DR: It is found that humans and mouse models with tubulointerstitial fibrosis had lower expression of key enzymes and regulators of fatty acid oxidation (FAO) and higher intracellular lipid deposition compared to controls, raising the possibility that correcting the metabolic defect in FAO may be useful for preventing and treating chronic kidney disease.
Journal ArticleDOI
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR).
Alberico L. Catapano,Ian D. Graham,Guy De Backer,Olov Wiklund,M. John Chapman,Heinz Drexel,Arno W. Hoes,Catriona Jennings,Ulf Landmesser,Terje R. Pedersen,Željko Reiner,Gabriele Riccardi,Marja-Riitta Taskinen,Lale Tokgozoglu,W. M. Monique Verschuren,Charalambos Vlachopoulos,David A. Wood,José Luis Zamorano +17 more
TL;DR: Authors/Task Force Members:Alberico L. Catapano (Chairperson) (Italy) , Ian Graham (Chair person) (Ireland) , Guy De Backer (Belgium), Olov Wiklund (Sweden)
References
More filters
Journal ArticleDOI
Bias in meta-analysis detected by a simple, graphical test
TL;DR: Funnel plots, plots of the trials' effect estimates against sample size, are skewed and asymmetrical in the presence of publication bias and other biases Funnel plot asymmetry, measured by regression analysis, predicts discordance of results when meta-analyses are compared with single large trials.
Journal Article
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
Andrew S. Levey,Josef Coresh,Kline Bolton,Bruce Culleton,Kathy Schiro Harvey,T. Alp Ikizler,Cynda Ann Johnson,Annamaria T. Kausz,Paul L. Kimmel,John W. Kusek,Adeera Levin,Kenneth L. Minaker,Robert Nelson,Helmut G. Rennke,Michael Steffes,Beth Witten,Ronald J. Hogg,Susan Furth,Kevin V. Lemley,Ronald J. Portman,George Schwartz,Joseph Lau,Ethan M Balk,Ronald D. Perrone,Tauqeer Karim,Lara Rayan,Inas Al-Massry,Priscilla Chew,Brad C. Astor,Deirdre De Vine,Garabed Eknoyan,Nathan W. Levin,Sally Burrows-Hudson,William F. Keane,Alan S. Kliger,Derrick Latos,Donna Mapes,Edith Oberley,Kerry Willis,George R. Bailie,Gavin J. Becker,Jerrilynn Burrowes,David Churchill,Allan J. Collins,William Couser,Dick DeZeeuw,Alan Garber,Thomas Golper,Frank A. Gotch,Antonio M. Gotto,Joel W. Greer,Richard H. Grimm,Ramon G. Hannah,Jaime Herrera Acosta,Ronald J. Hogg,Lawrence G. Hunsicker,Michael J. Klag,Saulo Klahr,Caya Lewis,Edmund G. Lowrie,Arthur J. Matas,Sally McCulloch,Maureen Michael,Joseph V. Nally,John M. Newmann,Allen R. Nissenson,Keith Norris,William F. Owen,Thakor G. Patel,Glenda Payne,Rosa A. Rivera-Mizzoni,David A. Smith,Robert A. Star,Theodore Steinman,Fernando Valderrábano,John Walls,Jean Pierre Wauters,Nanette Wenger,Josephine P. Briggs +78 more
TL;DR: In the early 1990s, the National Kidney Foundation (K/DOQI) developed a set of clinical practice guidelines to define chronic kidney disease and to classify stages in the progression of kidney disease.
Journal ArticleDOI
Effects of an angiotensin-converting -enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
TL;DR: Ramipril significantly reduces the rates of death, myocardial infarction, and stroke in a broad range of high-risk patients who are not known to have a low ejection fraction or heart failure.
Journal ArticleDOI
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Anthony C Keech,R. J. Simes,Philip J. Barter,James D. Best,Russell S. Scott,Marja-Riitta Taskinen,Peta M. Forder,Avinesh Pillai,Tamara M. Davis,Paul Glasziou,Paul L. Drury,Y A Kesäniemi,David R. Sullivan,D Hunt,Peter G. Colman,Michael C d'Emden,Malcolm J. Whiting,Christian Ehnholm,Markku Laakso +18 more
TL;DR: Fenofibrate did not significantly reduce the risk of the primary outcome of coronary events, but it did reduce total cardiovascular events, mainly due to fewer non-fatal myocardial infarctions and revascularisations.
Journal ArticleDOI
Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack
Stephen MacMahon,Bruce Neal,Christophe Tzourio,Anthony Rodgers,Mark Woodward,J. Cutler,Craig S. Anderson,John Chalmers,T. Ohkubo,M. G. Bouser,Stephen M. Davis,Geoffrey A. Donnan,L. Hansson,Stephen B. Harrap,K. R. Lees,L. Liu,G. Mancia,T. Omae,J. Reid,R. Sega,A. Terent,C. Warlow,N. Anderson,C. Bladin,B.C. Chambers,G. Gordon,N. Sharpe,Rory Collins,Peter Sandercock,John Simes,P. Sleight,A. Brnabic,S. Colman,L. Francis,A. Lee,L. Gong,M.-G. Bousser,T. Yamaguchi,F. William,Q. Deng,D. X. Hu,William Y.S. Wang,A. L. Wu,L. Y. Ma,Z. Y. Tao,V. Biousse,Karine Berthet,L. Ben Slamia,C. Le Denmat,S. Crespi,G. Foglia,C. Fujimoto,S. Matsumura,K. Marttala,M. Pettersson,M. Safwenberg,J. Fenton,Y. McIlvenna,R. Currie,H. Bartram,J. Briad,A. Clague,Y. Cleverly,M. Cosson,A. Culpan,D. Douglas,S. Flett,B. Gray,T. Holloway,A. Milne,R. Prasad,Y. Ratnasabapathy,A. Santos,M. Wills,T. Agnew,Neil Chapman,N. Lewis,B. Mullane +77 more
TL;DR: This blood-pressure-lowering regimen reduced the risk of stroke among both hypertensive and non-hypertensive individuals with a history of stroke or transient ischaemic attack, irrespective of their blood pressure.
Related Papers (5)
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
Colin Baigent,Martin J Landray,Christina Reith,Jonathan Emberson,David C. Wheeler,Charles R.V. Tomson,Christoph Wanner,Vera Krane,Alan Cass,Jonathan C. Craig,Bruce Neal,Lixin Jiang,Lai Seong Hooi,Adeera Levin,Lawrence Y. Agodoa,Mike Gaziano,Bertram L. Kasiske,Robert J. Walker,Ziad A. Massy,Bo Feldt-Rasmussen,Udom Krairittichai,Vuddidhej Ophascharoensuk,Bengt Fellström,Hallvard Holdaas,Vladimir Tesar,Andrzej Wiecek,Diederick E. Grobbee,Dick de Zeeuw,Carola Grönhagen-Riska,Tanaji Dasgupta,David Lewis,William G. Herrington,Marion Mafham,William Majoni,K Wallendszus,Richard H. Grimm,Terje R. Pedersen,Jonathan A. Tobert,Jane Armitage,Alex Baxter,Christopher Bray,Yiping Chen,Zhengming Chen,Michael Hill,Carol Knott,Sarah Parish,David Simpson,Peter Sleight,Alan Young,Rory Collins +49 more
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Anthony C Keech,R. J. Simes,Philip J. Barter,James D. Best,Russell S. Scott,Marja-Riitta Taskinen,Peta M. Forder,Avinesh Pillai,Tamara M. Davis,Paul Glasziou,Paul L. Drury,Y A Kesäniemi,David R. Sullivan,D Hunt,Peter G. Colman,Michael C d'Emden,Malcolm J. Whiting,Christian Ehnholm,Markku Laakso +18 more